A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Nifekalant
2020
JACC Case Reports
Preserved Fulltext
Atrial fibrillation along with accessory pathway-induced ventricular pre-excitation may be life-threatening due to the high risk of developing severe hypotension, ventricular fibrillation, and sudden death. We demonstrate nifekalant as an effective agent in the pharmacological cardioversion of atrial fibrillation with high-risk accessory pathways. (Level of Difficulty: Intermediate.) (J Am Coll Cardiol Case Rep 2020;2:235-9)
doi:10.1016/j.jaccas.2019.10.042
fatcat:laiolqtbh5esjkxyerds423zmq